Your browser doesn't support javascript.
loading
Noncovalent CDK12/13 dual inhibitors-based PROTACs degrade CDK12-Cyclin K complex and induce synthetic lethality with PARP inhibitor.
Niu, Tian; Li, Kailin; Jiang, Li; Zhou, Zhesheng; Hong, Ju; Chen, Xuankun; Dong, Xiaowu; He, Qiaojun; Cao, Ji; Yang, Bo; Zhu, Cheng-Liang.
Afiliação
  • Niu T; Institute of Pharmacology & Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, PR China.
  • Li K; Institute of Pharmacology & Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, PR China.
  • Jiang L; Institute of Pharmacology & Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, PR China.
  • Zhou Z; Institute of Pharmacology & Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, PR China.
  • Hong J; Institute of Pharmacology & Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, PR China.
  • Chen X; Institute of Pharmacology & Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, PR China.
  • Dong X; Innovation Institute for Artificial Intelligence in Medicine, Zhejiang University, Hangzhou, 310016, PR China; Cancer Center of Zhejiang University, Hangzhou, 310058, PR China; Hangzhou Institute of Innovative Medicine, Institute of Drug Discovery and Design, College of Pharmaceutical Sciences, Zhej
  • He Q; Institute of Pharmacology & Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, PR China; Center for Drug Safety Evaluation and Research of ZJU, Hangzhou, 310058, PR China; Innovation Institute for
  • Cao J; Institute of Pharmacology & Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, PR China; Innovation Institute for Artificial Intelligence in Medicine, Zhejiang University, Hangzhou, 310016, PR Chin
  • Yang B; Institute of Pharmacology & Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, PR China; Cancer Center of Zhejiang University, Hangzhou, 310058, PR China. Electronic address: yang924@zju.edu.cn.
  • Zhu CL; Institute of Pharmacology & Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, PR China; Center for Drug Safety Evaluation and Research of ZJU, Hangzhou, 310058, PR China; Innovation Institute for
Eur J Med Chem ; 228: 114012, 2022 Jan 15.
Article em En | MEDLINE | ID: mdl-34864331
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Proteína Quinase CDC2 / Poli(ADP-Ribose) Polimerases / Ciclinas / Quinases Ciclina-Dependentes / Inibidores de Proteínas Quinases / Inibidores de Poli(ADP-Ribose) Polimerases Limite: Humans Idioma: En Revista: Eur J Med Chem Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Proteína Quinase CDC2 / Poli(ADP-Ribose) Polimerases / Ciclinas / Quinases Ciclina-Dependentes / Inibidores de Proteínas Quinases / Inibidores de Poli(ADP-Ribose) Polimerases Limite: Humans Idioma: En Revista: Eur J Med Chem Ano de publicação: 2022 Tipo de documento: Article